

How Durvalumab and Tremelimumab Transform Liver Cancer Treatment
The emergence of Durvalumab (Imfinzi) in liver cancer treatment marks a significant advancement, particularly when used in combination with Tremelimumab (Imjudo), yielding notable survival benefits for those with unresectable hepatocellular carcinoma. Clinical trials highlight the efficacy of this combination, showcasing promising survival rates and an acceptable safety profile. This treatment paves the way for personalized […]
3 min read